🔎 Trials Near Me

Home › Alzheimer's Disease › New York › Newburgh

Alzheimer's Disease clinical trials in Newburgh, NY

5 studies for Alzheimer's Disease are looking for participants at sites in and around Newburgh (within about 30 miles). Open a study to see who can join and how to contact the study team.

Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →

A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3)

RecruitingPhase 3
  • Local Institution - 1656, New Windsor · 2 mi away
Ages 55 to 90 · All sexes · Updated Sep 28, 2026 · NCT06937229

A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)

RecruitingPhase 3
  • Mid Hudson Medical Research PLLC, New Windsor · 2 mi away
Ages 55 to 90 · All sexes · Updated Sep 22, 2026 · NCT06585787

A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-1)

RecruitingPhase 3
  • Mid Hudson Medical Research, New Windsor · 2 mi away
Ages 55 to 90 · All sexes · Updated Sep 16, 2026 · NCT07011732

Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986368, for the Treatment of Agitation in Participants With Alzheimer's Disease

RecruitingPhase 2
  • Mid Hudson Medical Research, New Windsor · 2 mi away
Ages 55 to 90 · All sexes · Updated Sep 1, 2026 · NCT06808984

A Clinical Study of MK-2214 in People With Early Alzheimer's Disease (MK-2214-004)

RecruitingPhase 2
  • Mid Hudson Medical Research ( Site 1050), New Windsor · 2 mi away
Ages 50 to 85 · All sexes · Updated Aug 26, 2026 · NCT07033494

About Alzheimer's Disease

Alzheimer's disease is a brain disorder that slowly destroys memory and thinking skills. It's the most common cause of dementia among older adults.

More about Alzheimer's Disease on MedlinePlus

Alzheimer's Disease trials in other cities

Other studies in Newburgh

From ClinicalTrials.gov, data retrieved Oct 6, 2026. Each study sets its own eligibility; the study team decides who can join.